Sckisel, Gail D Mirsoian, Annie Bouchlaka, Myriam N Tietze, Julia K Chen, Mingyi Blazar, Bruce R Murphy, William J
Published in
Cancer immunology, immunotherapy : CII
We have demonstrated that immunostimulatory therapies such as interleukin-2 (IL-2) and anti-CD40 (αCD40) can be combined to deliver synergistic anti-tumor effects. While this strategy has shown success, efficacy varies depending on a number of factors including tumor type and severe toxicities can be seen. We sought to determine whether blockade of...
Vik-Mo, Einar Osland Nyakas, Marta Mikkelsen, Birthe Viftrup Moe, Morten Carstens Due-Tønnesen, Paulina Suso, Else Marit Inderberg Sæbøe-Larssen, Stein Sandberg, Cecilie Brinchmann, Jan E Helseth, Eirik
...
Published in
Cancer immunology, immunotherapy : CII
These findings suggest that vaccination against glioblastoma stem cells is safe, well-tolerated, and may prolong progression-free survival.
Mandl, Stefanie J Rountree, Ryan B Dalpozzo, Katie Do, Lisa Lombardo, John R Schoonmaker, Peter L Dirmeier, Ulrike Steigerwald, Robin Giffon, Thierry Laus, Reiner
...
Published in
Cancer immunology, immunotherapy : CII
MVA-BN®-HER2 is a new candidate immunotherapy designed for the treatment of HER-2-positive breast cancer. Here, we demonstrate that a single treatment with MVA-BN®-HER2 exerts potent anti-tumor efficacy in a murine model of experimental pulmonary metastasis. This anti-tumor efficacy occurred despite a strong tumor-mediated immunosuppressive environ...
Bouwhuis, Marna G Gast, Andreas Figl, Adina Eggermont, Alexander M M Hemminki, Kari Schadendorf, Dirk Kumar, Rajiv
Published in
Cancer immunology, immunotherapy : CII
The appearance of vitiligo and spontaneous regression of the primary lesion in melanoma patients illustrate a relationship between tumor immunity and autoimmunity. T lymphocytes play a major role both in tumor immunity and autoimmunity. CD28, Cytotoxic T lymphocyte antigen 4 (CTLA4) and inducible costimulator (ICOS) molecules are important secondar...
Andersen, Mads Hald Sørensen, Rikke Baek Schrama, David Svane, Inge Marie Becker, Jürgen C Thor Straten, Per
Published in
Cancer immunology, immunotherapy : CII
Harnessing of the immune system by the development of 'therapeutic' vaccines, for the battle against cancer has been the focus of tremendous research efforts over the past two decades. As an illustration of the impressive amounts of data gathered over the past years, numerous antigens expressed on the surface of cancer cells, have been characterize...
Frederiksen, Klaus Stensgaard Lundsgaard, Dorthe Freeman, Jeremy A Hughes, Steven D Holm, Thomas L Skrumsager, Birte K Petri, Andreas Hansen, Lasse T McArthur, Grant A Davis, Ian D
...
Published in
Cancer immunology, immunotherapy : CII
IL-21 was biologically active at all dose levels administered with evidence of in vivo NK cell and CD8(+) T cell activation.
Erik Ames William Murphy
Published in
Cancer Immunology Immunotherapy
The past decade has witnessed a burgeoning of research and further insight into the biology and clinical applications of natural killer (NK) cells. Once thought to be simple innate cells important only as cytotoxic effector cells, our understanding of NK cells has grown to include memory-like responses, the guidance of adaptive responses, tissue re...
